CYTB323K12201: A Phase 2, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

Objective

Clinical Trial Details

Principal Investigator(s)
Xavier Andrade-Gonzalez, MD

Clinical Trial Categories

  • Cancer
Contact
Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org

Location

  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000